AR031597A1 - Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 - Google Patents
Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3Info
- Publication number
- AR031597A1 AR031597A1 ARP010103261A ARP010103261A AR031597A1 AR 031597 A1 AR031597 A1 AR 031597A1 AR P010103261 A ARP010103261 A AR P010103261A AR P010103261 A ARP010103261 A AR P010103261A AR 031597 A1 AR031597 A1 AR 031597A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- hydrogen
- phenyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos piperidinos de la formula (1) en forma libre o de sal, en donde: Ar1 es fenilo sustituido por uno o más átomos de halogeno, Ar2 es fenilo o naftilo que está insustituido o sustituido por uno o más sustituyentes seleccionados a partir de halogeno, ciano, hidroxilo, nitro, alquilo de 1 a 8 átomos de carbono, haloalquilo de 1 a 8 átomos de carbono, alcoxilo de 1 a 8 átomos de carbono, alcoxicarbonilo de 1 a 8 átomos de carbono, R1 es hidrogeno o alquilo de 1 a 8 átomos de carbono opcionalmente sustituido por hidroxilo, alcoxilo de 1 a 8 átomos de carbono, aciloxilo, -N(R2)R3, halogeno, carboxilo, alcoxicarbonilo de 1 a 8 átomos de carbono, -CON(R4)R5 o por un grupo orgánico cíclico monovalente, R2 y R3 son cada uno independientemente hidrogeno o alquilo de 1 a 8 átomos de carbono, o R2 es hidrogeno y R3 es acilo o ûSO2R6, o R2 y R3, junto con el átomo de nitrogeno con el que están unidos, denotan un grupo heterocíclico de 5 o 6 miembros, R4 y R5 son cada uno independientemente hidrogeno, o alquilo de 1 a 8 átomos de carbono, o R4 y R5, junto con el átomo de nitrogeno con el que están unidos, denotan un grupo heterocíclico de 5 o 6 miembros, R6 es alquilo de 1 a 8 átomos de carbono, haloalquilo de 1 8 átomos de carbono, o fenilo opcionalmente sustituido por alquilo de 1 a 8 átomos de carbono, y n es 1, 2, 3 o 4, con la condicion de que cuando Ar1 es p-clorofenilo, y R1 es hidrogeno, Ar2 no sea fenilo o p-nitrofenilo; un proceso para su preparacion, composiciones farmacéuticas y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores CCR-3. Compuestos piperidinos de la formula (1) en forma libre o de sal, en donde: Ar1 es fenilo sustituido por uno o más átomos de halogeno, Ar2 es fenilo o naftilo que está insustituido o sustituido por uno o más sustituyentes seleccionados a partir de halogeno, ciano, hidroxilo, nitro, alquilo de 1 a 8 átomos de carbono, haloalquilo de 1 a 8 átomos de carbono, alcoxilo de 1 a 8 átomos de carbono, alcoxicarbonilo de 1 a 8 átomos de carbono, R1 es hidrogeno o alquilo de 1 a 8 átomos de carbono opcionalmente sustituido por hidroxilo, alcoxilo de 1 a 8 átomos de carbono, aciloxilo, -N(R2)R3, halogeno, carboxilo, alcoxicarbonilo de 1 a 8 átomos de carbono, -CON(R4)R5 o por un grupo orgánico cíclico monovalente, R2 y R3 son cada uno independientemente hidrogeno o alquilo de 1 a 8 átomos de carbono, o R2 es hidrogeno y R3 es acilo o ûSO2R6, o R2 y R3, junto con el átomo de nitrogeno con el que están unidos, denotan un grupo heterocíclico de 5 o 6 miembros, R4 y R5 son cada uno independientemente hidrogeno, o alquilo de 1 a 8 átomos de carbono, o R4 y R5, junto con el átomo de nitrogeno con el que están unidos, denotan un grupo heterocíclico de 5 o 6 miembros, R6 es alquilo de 1 a 8 átomos de carbono, haloalquilo de 1 8 átomos de carbono, o fenilo opcionalmente sustituido por alquilo de 1 a 8 átomos de carbono, y n es 1, 2, 3 o 4, con la condicion de que cuando Ar1 es p-clorofenilo, y R1 es hidrogeno, Ar2 no sea fenilo o p-nitrofenilo; un proceso para su preparacion, composiciones farmacéuticas y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores CCR-3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0017174A GB0017174D0 (en) | 2000-07-12 | 2000-07-12 | Organic compounds |
| GB0023326A GB0023326D0 (en) | 2000-09-22 | 2000-09-22 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031597A1 true AR031597A1 (es) | 2003-09-24 |
Family
ID=26244644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103261A AR031597A1 (es) | 2000-07-12 | 2001-07-10 | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6670379B2 (es) |
| EP (1) | EP1303488B1 (es) |
| JP (1) | JP2004502756A (es) |
| KR (1) | KR20030036603A (es) |
| CN (1) | CN1184204C (es) |
| AR (1) | AR031597A1 (es) |
| AT (1) | ATE447553T1 (es) |
| AU (2) | AU2001281972B2 (es) |
| BR (1) | BR0112456A (es) |
| CA (1) | CA2412941C (es) |
| CZ (1) | CZ200375A3 (es) |
| DE (1) | DE60140366D1 (es) |
| ES (1) | ES2334886T3 (es) |
| HU (1) | HUP0301341A2 (es) |
| IL (1) | IL153661A0 (es) |
| MX (1) | MXPA02012848A (es) |
| MY (1) | MY126139A (es) |
| NO (1) | NO324760B1 (es) |
| NZ (1) | NZ523414A (es) |
| PE (1) | PE20020616A1 (es) |
| PL (1) | PL358673A1 (es) |
| PT (1) | PT1303488E (es) |
| SK (1) | SK272003A3 (es) |
| TW (1) | TWI227231B (es) |
| WO (1) | WO2002004420A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO2002030898A1 (en) * | 2000-10-09 | 2002-04-18 | Novartis Ag | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists |
| GB0114699D0 (en) * | 2001-06-15 | 2001-08-08 | Novartis Ag | Organic compounds |
| PL1670482T5 (pl) * | 2003-09-16 | 2022-10-03 | Covis Pharma Gmbh | Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| MX2017013275A (es) | 2015-04-15 | 2018-01-26 | Araxes Pharma Llc | Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos. |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| CA3005089A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002510327A (ja) | 1997-07-25 | 2002-04-02 | メルク エンド カンパニー インコーポレーテッド | 環状アミンケモカイン受容体活性調節剤 |
| US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| BR9915403A (pt) | 1998-11-17 | 2001-08-14 | Hoffmann La Roche | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 |
| AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| TR200102800T2 (tr) * | 1999-03-26 | 2002-01-21 | Astrazeneca Ab | Yeni bileşikler. |
-
2001
- 2001-07-09 TW TW090116691A patent/TWI227231B/zh not_active IP Right Cessation
- 2001-07-10 IL IL15366101A patent/IL153661A0/xx unknown
- 2001-07-10 BR BR0112456-0A patent/BR0112456A/pt not_active IP Right Cessation
- 2001-07-10 ES ES01960488T patent/ES2334886T3/es not_active Expired - Lifetime
- 2001-07-10 EP EP01960488A patent/EP1303488B1/en not_active Expired - Lifetime
- 2001-07-10 PL PL01358673A patent/PL358673A1/xx not_active Application Discontinuation
- 2001-07-10 MY MYPI20013274A patent/MY126139A/en unknown
- 2001-07-10 PE PE2001000683A patent/PE20020616A1/es not_active Application Discontinuation
- 2001-07-10 US US10/332,642 patent/US6670379B2/en not_active Expired - Fee Related
- 2001-07-10 AT AT01960488T patent/ATE447553T1/de not_active IP Right Cessation
- 2001-07-10 JP JP2002509087A patent/JP2004502756A/ja active Pending
- 2001-07-10 NZ NZ523414A patent/NZ523414A/en unknown
- 2001-07-10 WO PCT/EP2001/007941 patent/WO2002004420A1/en active IP Right Grant
- 2001-07-10 KR KR10-2003-7000445A patent/KR20030036603A/ko not_active Application Discontinuation
- 2001-07-10 AU AU2001281972A patent/AU2001281972B2/en not_active Ceased
- 2001-07-10 SK SK27-2003A patent/SK272003A3/sk not_active Application Discontinuation
- 2001-07-10 DE DE60140366T patent/DE60140366D1/de not_active Expired - Lifetime
- 2001-07-10 AR ARP010103261A patent/AR031597A1/es unknown
- 2001-07-10 CZ CZ200375A patent/CZ200375A3/cs unknown
- 2001-07-10 PT PT01960488T patent/PT1303488E/pt unknown
- 2001-07-10 CN CNB018126111A patent/CN1184204C/zh not_active Expired - Fee Related
- 2001-07-10 AU AU8197201A patent/AU8197201A/xx active Pending
- 2001-07-10 HU HU0301341A patent/HUP0301341A2/hu unknown
- 2001-07-10 CA CA2412941A patent/CA2412941C/en not_active Expired - Fee Related
- 2001-07-10 MX MXPA02012848A patent/MXPA02012848A/es active IP Right Grant
-
2003
- 2003-01-10 NO NO20030135A patent/NO324760B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60140366D1 (de) | 2009-12-17 |
| NO20030135D0 (no) | 2003-01-10 |
| ATE447553T1 (de) | 2009-11-15 |
| NO20030135L (no) | 2003-02-19 |
| ES2334886T3 (es) | 2010-03-17 |
| CA2412941A1 (en) | 2002-01-17 |
| BR0112456A (pt) | 2003-07-22 |
| PE20020616A1 (es) | 2002-08-02 |
| EP1303488A1 (en) | 2003-04-23 |
| KR20030036603A (ko) | 2003-05-09 |
| TWI227231B (en) | 2005-02-01 |
| CA2412941C (en) | 2011-01-04 |
| JP2004502756A (ja) | 2004-01-29 |
| PL358673A1 (en) | 2004-08-09 |
| MY126139A (en) | 2006-09-29 |
| WO2002004420A1 (en) | 2002-01-17 |
| NO324760B1 (no) | 2007-12-10 |
| US20030176460A1 (en) | 2003-09-18 |
| HUP0301341A2 (hu) | 2003-08-28 |
| AU2001281972B2 (en) | 2004-06-03 |
| CZ200375A3 (cs) | 2003-04-16 |
| AU8197201A (en) | 2002-01-21 |
| IL153661A0 (en) | 2003-07-06 |
| NZ523414A (en) | 2004-07-30 |
| EP1303488B1 (en) | 2009-11-04 |
| CN1441780A (zh) | 2003-09-10 |
| PT1303488E (pt) | 2010-01-19 |
| CN1184204C (zh) | 2005-01-12 |
| SK272003A3 (en) | 2003-07-01 |
| US6670379B2 (en) | 2003-12-30 |
| MXPA02012848A (es) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR035548A1 (es) | Compuestos organicos | |
| AR028531A1 (es) | Compuestos organicos | |
| PE20050015A1 (es) | Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| ES2121441T3 (es) | Nuevos derivados de 3,5 -dioxo - (2h,4h) - 1,2,4 - triazina,su preparacion y aplicacion como farmaco | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR033525A1 (es) | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento | |
| CO6150144A2 (es) | Inhibidores de proteina tirosina fosfatasa humana y metodos de uso | |
| CL2004000917A1 (es) | Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa | |
| CO5180557A1 (es) | Derivados de 1,4-diazabiciclo[3.2.2]nonan-4-carboxilatos y carboxamidas y sus composiciones farmaceuticas . | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| CO5261559A1 (es) | Antagonistas de neurokinina selectivos | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| AR049401A1 (es) | Aza-biciclononanos | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| DK1200426T3 (da) | Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner | |
| CO5160347A1 (es) | Derivados de acido carbamico | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
| AR029821A1 (es) | Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |